Pharmaceutical Patent Strategy

The Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman) created the framework for pharmaceutical patent strategy: DUAL PURPOSE: (1) enable generic entry through Abbreviated New Drug Application (ANDA) pathway — generics prove bioequivalence rather than conducting full clinical trials; (2) partially compensate innovators for patent time lost during FDA regulatory review — via patent term extension; ANDA PATHWAY: a generic applicant can file an ANDA at any time; the generic applicant must certify regarding each listed Orange Book patent: PARAGRAPH I: patent expired; PARAGRAPH II: patent does not cover the generic; PARAGRAPH III: generic will not launch until after patent expiration; PARAGRAPH IV: patent is invalid OR will not be infringed by the generic (most commercially significant); PARAGRAPH IV = PATENT CHALLENGE: a Paragraph IV certification is a 'constructive act of infringement' under § 271(e)(2); it gives the brand company the right to sue immediately even before the generic is marketed; 30-MONTH STAY: if the NDA holder (brand company) sues the generic within 45 days of receiving the Paragraph IV notice, FDA approval is automatically stayed for 30 months (or until final court decision if earlier); this 30-month stay is the brand company's key tactical weapon to delay generic entry; GENERIC FIRST-FILER EXCLUSIVITY: the FIRST generic to file a successful Paragraph IV challenge gets 180 days of generic market exclusivity — they can block all subsequent generics for 6 months; this incentivizes generic companies to challenge weak pharma patents; WHY PATENT STRATEGY MATTERS: a brand company with a strong, well-listed Orange Book patent estate can defend its market exclusivity; a weak or incomplete patent estate is vulnerable to ANDA challenges; the patent cliff (sudden revenue loss at exclusivity expiration) can be 80-90% of sales lost in the first year.

Orange Book listing is governed by specific regulatory requirements that determine what patents qualify: WHAT THE ORANGE BOOK IS: a publicly available FDA database (Approved Drug Products with Therapeutic Equivalence Evaluations) listing NDA-approved drugs and their associated patents; WHICH PATENTS QUALIFY FOR LISTING: 21 C.F.R. § 314.53: NDA holders must submit patents that 'claim' the drug or a method of using the drug for which the applicant submitted the NDA; THREE TYPES OF LISTABLE PATENTS: (1) DRUG SUBSTANCE (COMPOSITION OF MATTER): patent claims the active ingredient itself (the molecule); strongest patent; generic must prove it is invalid or its product does not have the same structure; (2) DRUG PRODUCT (FORMULATION): patent claims the formulation (specific combination of active + inactive ingredients, specific salt form, specific polymorph, specific coating); generic must prove its formulation does not infringe; (3) METHOD OF USE: patent claims a specific approved method of use (indication) covered by the NDA; generic can file a 'Paragraph III carve-out' to exclude the patented use from its labeling (label 'skinny labeling') and avoid the method-of-use patent; WHAT CANNOT BE LISTED: PROCESS PATENTS: the method of manufacturing the drug; cannot be listed even if they claim the drug; must be enforced through direct infringement suits (not Hatch-Waxman); METABOLITE PATENTS: patents claiming a metabolite of the drug (the compound the body converts the drug into) if the metabolite is not itself the drug substance; PACKAGING AND DEVICE PATENTS: device or container patents; STRATEGIC IMPLICATIONS: list every qualifying patent as soon as it issues (gives a new 30-month stay for each Paragraph IV challenge); patent on the drug substance is hardest to design around; formulation and method-of-use patents can be targeted via skinny labeling or design-around formulations.

Patent term extension (PTE) compensates pharma companies for patent time lost during FDA regulatory review: STATUTORY BASIS: 35 U.S.C. § 156 (Hatch-Waxman PTE); ELIGIBLE PATENTS: patents claiming (1) the drug substance (the active moiety); (2) a method of using the drug substance; (3) the drug product (approved formulation); MAXIMUM EXTENSION: 5 years; cannot extend beyond 14 years from NDA approval date; CALCULATION: extension = (1/2 of Investigational New Drug (IND) period) + (NDA review period, from filing to approval); only ONE patent per product can receive PTE (NDA holder chooses the most commercially valuable patent); APPLICATION TIMING: must apply to USPTO within 60 days of FDA approval; PEDIATRIC EXCLUSIVITY (BPCA): separate 6-month extension for conducting qualifying pediatric clinical studies at FDA's request; adds 6 months to ALL patents AND to the 5-year NCE exclusivity; FDA grants this; PRACTICAL EXAMPLE: drug compound patent filed in 2005; clinical trials: 2007-2015 (8 years); NDA approved 2016; patent expires 2025 (20 years from filing); PTE = (½ of IND period from 2007) + full NDA review (say 2 years); maximum is whichever is less: 5 years; 14 years from approval = 2030; so PTE extends to 2030; pediatric exclusivity adds 6 months to 2030 = April 2031; NCE (NEW CHEMICAL ENTITY) EXCLUSIVITY: completely separate from PTE; FDA regulatory data exclusivity (5 years for NCE; 3 years for new indication); FDA cannot approve any ANDA during this period regardless of patent status; TIMING COORDINATION: PTE + NCE exclusivity + Orange Book patents + continuation applications = the full suite of pharma exclusivity tools.

Evergreening refers to strategies that extend effective exclusivity beyond the original compound patent: DEFINITION: 'evergreening' describes the practice of obtaining additional patents on secondary features of a drug to delay generic entry beyond the expiration of the original composition-of-matter patent; LEGAL STATUS: evergreening strategies are legal under US patent law as long as each patent covers a genuine, novel, and non-obvious invention; critics argue these strategies exploit patent law to limit access to affordable medicines; defenders argue they incentivize continued innovation; COMMON EVERGREENING STRATEGIES: (1) FORMULATION PATENTS: patenting specific salt forms, polymorphs (crystal structures), particle sizes, coatings, or controlled-release formulations of the active ingredient; challenge: Paragraph IV — generic argues same formulation is obvious over prior art; (2) ENANTIOMER / METABOLITE PATENTS: the original compound may be a racemate; patent the specific active enantiomer separately (Forest Labs's Lexapro from Celexa); patentee argues the enantiomer has unexpected therapeutic properties; (3) METHOD OF USE PATENTS / NEW INDICATIONS: patent a new approved indication; generic can skinny-label but may be liable for induced infringement if most uses are the patented indication (GlaxoSmithKline v. Teva, Fed. Cir. 2021); (4) PEDIATRIC EXCLUSIVITY: conduct pediatric studies at FDA's request → 6 additional months on all patents + NCE exclusivity; (5) DOSING REGIMEN PATENTS: specific once-daily dosing; specific dosing intervals; specific patient selection criteria; (6) COMBINATION PRODUCT PATENTS: a fixed-dose combination of two existing drugs; if the combination has unexpected synergistic effects, it may be patentable; PARAGRAPH IV CHALLENGES: evergreening patents are prime targets for Paragraph IV ANDA challenges and IPR petitions; courts scrutinize method-of-use and formulation patents for obviousness; secondary considerations (commercial success; unexpected results) are critical to defending these patents.

Responding to a Paragraph IV challenge requires immediate and strategic action: NOTICE REQUIREMENTS: the generic applicant must send written notice of the Paragraph IV certification to the NDA holder and patent owner within 20 days of FDA notification; the notice must identify the NDA, each patent challenged, and the factual and legal basis for invalidity or non-infringement; THE 45-DAY WINDOW: the brand company must file suit within 45 days of receiving the notice to trigger the 30-month stay; filing suit = a complaint in district court for patent infringement (§ 271(e)(2)); if the brand company does NOT sue within 45 days, the 30-month stay does not apply and FDA can approve the generic immediately upon completing review; IMMEDIATE RESPONSE STEPS: (1) confirm receipt and parse the notice carefully (which patents challenged; which grounds raised); (2) conduct rapid patent landscape review (are the challenged patents strong?; what non-infringement arguments might the generic have?); (3) evaluate the Paragraph IV grounds: invalidity (prior art; § 112); non-infringement (different formulation; label carve-out?); (4) decide whether to sue (almost always yes — triggers 30-month stay); (5) file infringement suit in the appropriate district; LITIGATION STRATEGY: Markman hearing: claim construction of disputed terms; often dispositive for non-infringement defenses; generic's ANDA product: brand must compare the ANDA product to the claims; brand gets access to the ANDA and supporting data during discovery; SETTLEMENT OPTIONS: authorized generic agreement: brand licenses generic to sell an authorized generic (same formulation; lower price) — gives brand a revenue share during generic period; pay-for-delay: Federal Trade Commission v. Actavis (S.Ct. 2013): pay-for-delay settlements (where brand pays generic to delay entry) are subject to antitrust scrutiny under rule of reason (can be anticompetitive); IPR AS A DEFENSE TOOL: the generic company can also file an IPR petition on the Orange Book patents; IPR institution has no impact on the 30-month stay (the stay continues regardless); but IPR can threaten the patent and may lead to early settlement.